<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Epidemiology and outcome of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) in the United States is not well recognized </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> became reportable to the Surveillance, Epidemiology, and End Results Program (SEER) in 2001 </plain></SENT>
<SENT sid="2" pm="."><plain>We report first study of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> among large population in the Veteran Affair system </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHODS: There are approximately 127 VA Medical Centers diagnosing and/or treating <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>The data collected by the medical centers <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registries is aggregated as the VA Central <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Registry (VACCR) </plain></SENT>
<SENT sid="5" pm="."><plain>We used the VACCR to analyze VA patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> diagnosed between 1995 and 2006 </plain></SENT>
<SENT sid="6" pm="."><plain>The cases were identified using <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>-03 histology codes for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: A total of 2242 MDS cases were registered during the period analyzed </plain></SENT>
<SENT sid="8" pm="."><plain>The median overall survival (OS) was 2.1 years, but varied by French-American-British category </plain></SENT>
<SENT sid="9" pm="."><plain>Median OS for patients with RA, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> was 3.4, 4.9, and 0.7 years, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>No differences in OS were observed by race </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: Outcome of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in the VA was similar to what is described in literature and reported by the SEER Program </plain></SENT>
<SENT sid="12" pm="."><plain>Appropriate coding for WHO subtypes, IPSS and treatment details are needed in <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> registries to facilitate comparisons across populations </plain></SENT>
</text></document>